Workflow
Cai Jing Wang
icon
Search documents
腾讯发布并开源混元世界模型1.5:支持实时创建3D世界并动态交互
Cai Jing Wang· 2025-12-17 07:36
今年7月,腾讯混元团队发布混元3D世界模型1.0,支持文本或单张图片输入生成兼容图形学管线的3D 场景;10月,混元团队发布世界模型1.1,支持多视图或视频一键创造3D世界。此次发布的混元世界模 型1.5进一步带来了世界建模的全新可能性。 同时,混元世界模型1.5(WorldPlay)首次开源了业界最系统、最全面的实时世界模型框架,涵盖数据、 训练、流式推理部署等全链路、全环节,并提出了重构记忆力、长上下文蒸馏、基于3D的自回归扩散 模型强化学习等算法模块。 12月17日,腾讯混元发布世界模型1.5(Tencent HY WorldPlay),用户输入文字描述或者图片即可创建专 属的互动世界,通过键盘、鼠标或手柄实时控制虚拟相机的移动和转向,像玩游戏一样自由探索AI生 成的世界。这是国内首个开放体验的实时世界模型。 ...
金花股份:董事长邢雅江收证监会陕西监管局行政处罚,被给予警告并处以350万元罚款
Cai Jing Wang· 2025-12-17 06:05
邢雅江的上述行为违反《证券法》第七十八条第一款的规定,构成《证券法》第一百九十七条第一款所 述违法行为。 根据当事人违法行为的事实、性质、情节及社会危害程度,依据《证券法》第一百九十七条第一款的规 定,陕西监管局决定:对邢雅江给予警告,并处以 350 万元罚款。 近日,金花股份(600080)发布公告称,董事长邢雅江因涉嫌犯罪于2024年4月至7月被公安机关取保候 审,邢雅江作为金花企业(集团)股份有限公司(以下简称金花股份)董事长,未及时将前述事项报告 金花股份,并及时履行信息披露义务。直至2024年8月24日,金花股份才对外披露相关事项。 ...
富泽人寿及其分支机构获批开业,注册资本为170亿元
Cai Jing Wang· 2025-12-17 05:38
同时,批准冯毅富泽人寿保险股份有限公司董事、董事长的任职资格;批准谢祝锋富泽人寿保险股份有 限公司总经理的任职资格。批准富泽人寿保险股份有限公司筹建浙江、黑龙江、江苏等省级分公司及其 他分支机构,并准予开业。 此外,国家金融监督管理总局山东监管局发布批复,同意富泽人寿保险股份有限公司受让君康人寿保险 股份有限公司的保险业务,具体为双方共同签署的《保险业务转让协议》约定的转让标的。转让行为应 严格遵守有关法律法规和监管规定,不得损害投保人、被保险人和受益人的合法权益。 12月16日,国家金融监督管理总局山东监管局发布批复,同意富泽人寿保险股份有限公司开业,并接受 山东金融监管局的属地监督管理。批准富泽人寿保险股份有限公司注册资本为170亿元人民币。 富泽人寿保险股份有限公司股东构成、出资额和持股比例如下:济南金投控股集团有限公司,出资84.5 亿元人民币,持股比例49.71%;中国保险保障基金有限责任公司,出资60亿元人民币,持股比例 35.29%;中国人保(601319)资产管理有限公司,出资19.5亿元人民币,持股比例11.47%;济南政金通 达投资管理有限公司,出资6亿元人民币,持股比例3.53%。 ...
和铂医药:与百时美施贵宝共同开发新一代多特异性抗体疗法
Cai Jing Wang· 2025-12-17 05:27
Core Viewpoint - The announcement highlights a long-term global strategic collaboration and licensing agreement between the company and Bristol-Myers Squibb to jointly develop next-generation multispecific antibody therapies [1] Group 1: Partnership Details - The company will collaborate with Bristol-Myers Squibb to advance and accelerate multispecific antibody discovery projects [1] - The agreement includes an upfront payment of $90 million to the company [1] - If Bristol-Myers Squibb decides to pursue all potential projects, the company could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties based on future product net sales [1]
科伦博泰生物:与宜联生物达成和解后后者6款ADC管线收入需按比例分成
Cai Jing Wang· 2025-12-17 05:27
Core Viewpoint - The company has reached a settlement agreement with Suzhou Yilian Biopharmaceutical Co., Ltd. and other parties to resolve several disputes, including criminal accusations and civil lawsuits related to business secrets and company interests [1] Group 1: Settlement Agreement - The settlement aims to save time and costs associated with legal proceedings [1] - Yilian Biopharmaceutical is required to share a certain percentage of revenue and net profit from specific products (YL201, YL202, YL211, YL212, YL221, and YL222) generated before and after the effective date of the settlement [1] - The board believes that the settlement will not have a significant adverse impact on the company's financial condition and operations [1]
祥源系百亿金融产品爆雷,俞发祥股份遭冻结
Cai Jing Wang· 2025-12-17 04:51
Core Viewpoint - The "Xiangyuan System" is facing a liquidity crisis due to the inability to redeem over 200 financial products, with total outstanding funds exceeding 10 billion yuan, leading to significant stock price declines for its listed companies [1][2]. Group 1: Financial Crisis Details - Xiangyuan Group's financial products, which were marketed as low-risk with expected annual returns of 4%-5%, are linked to accounts receivable from various real estate projects [2]. - Since November 28, multiple financial asset income rights products guaranteed by Xiangyuan Group have failed to meet redemption obligations, resulting in a total outstanding amount exceeding 10 billion yuan [1][2]. - The Zhejiang Jin Asset Operation Co., Ltd. has had its trading qualifications revoked, cutting off the "borrow new to repay old" channel, exacerbating the liquidity crisis [2]. Group 2: Impact on Listed Companies - Both Xiangyuan Cultural Tourism and Jiaojian Co., Ltd. have seen their stock prices drop over 20% and 30%, respectively, following the financial turmoil [1]. - The controlling shareholder of Xiangyuan Cultural Tourism has had 99.06% of its shares judicially frozen, which represents 37.03% of the company's total share capital [5]. - The controlling shareholder of Jiaojian Co., Ltd. has had 44.32% of its shares frozen, with 7.31% being judicially frozen and 4.43% pledged [9][10]. Group 3: Government and Regulatory Response - Local government and relevant departments have initiated investigations and measures to address the debt risks associated with Xiangyuan Group [5][8]. - A working group from Shaoxing City has been deployed to assist Xiangyuan Group in managing its assets and liabilities to ensure normal operations [5][8].
阿联酋航空迪拜至北京航线将推出豪华经济舱产品
Cai Jing Wang· 2025-12-17 04:05
(阿联酋航空) 作为深耕中国市场的重要布局,阿联酋航空今年7月已完成深圳、杭州两条全新航线的开通,且均配备 新版客舱产品——深圳-迪拜航线采用四舱版波音777客机,杭州-迪拜航线则由全新空客A350执飞。同 期,上海往返迪拜的每日两班客运航班中,一班也已启用焕新版四舱波音777-300ER客机。此次北京航 线升级后,2026年2月起,中国内地乘客可在北上深杭四大航点体验其最新客舱服务。 此次投用的焕新版波音777-300ER客机,客舱内饰全面升级,共设8个头等舱私人包间、40个1-2-1布局 商务舱座位、24个豪华经济舱座位及260个新一代经济舱座位。其中屡获行业大奖的豪华经济舱为核心 亮点,提供可后躺皮革座椅、完整腿脚部支撑、13.3英寸个人屏幕等设施,部分航班还配备免费洗漱包 及独家供应的夏桐2017年份起泡酒。 近日,阿联酋航空宣布,自2026年2月1日起,其迪拜往返北京的EK306/EK307航班将正式部署焕新版波 音777-300ER客机。此举标志着北京成为该航司在中国内地继深圳、上海、杭州之后,第四个引入其旗 舰豪华经济舱产品的战略航点,进一步完善了其在华高端客舱服务网络。 ...
卓正医疗通过港交所聆讯,专注服务中高端医疗服务市场
Cai Jing Wang· 2025-12-17 03:43
Group 1 - The core viewpoint of the article is that卓正医疗 has passed the main board listing hearing and is focusing on the mid-to-high-end medical service market in China, targeting affluent customers [1] -卓正医疗 aims to become the third largest private mid-to-high-end comprehensive medical service provider in China by 2024, with a market share of 2% in this segment and approximately 0.1% in the broader mid-to-high-end market [1] - The private mid-to-high-end medical service market in China is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2020 to 2024, and is expected to continue growing at a CAGR of 14.3% from 2024 to 2029 [1] Group 2 -卓正医疗 has established a network of medical service institutions in several developed cities in China, with plans to operate 19 facilities by October 28, 2025, and has clinics in Singapore and Malaysia [1]
卡夫亨氏宣布任命Steve Cahillane为公司首席执行官,自2026年1月1日起生效
Cai Jing Wang· 2025-12-17 03:38
Group 1 - Kraft Heinz announced the appointment of Steve Cahillane as the new CEO, effective January 1, 2026 [1] - Cahillane will also join the company's board and serve as CEO of the "Global Flavor Enhancement Company" after the planned split into two independent publicly traded companies [1] - Current CEO Carlos Abrams-Rivera will step down on January 1 and will serve as a consultant until March 6, 2026, to ensure a smooth leadership transition [1]
广州大力发展新能源汽车,加快城市公共服务车辆的电动化替代
Cai Jing Wang· 2025-12-17 03:34
Group 1 - The Guangzhou Municipal Government has released the "Beautiful Guangzhou Construction Planning Outline (2025-2035)" [1] - The plan emphasizes the adoption of advanced processes and technologies for energy-saving transformations in industries such as petrochemicals, steel, cement, and automobiles [1] - It aims to accelerate the upgrade of equipment and products, pushing industries like petrochemicals to reach peak emissions as soon as possible [1] Group 2 - The initiative includes the promotion of the first batch of pilot cities for vehicle-network interaction on a large scale, enhancing vehicle and network collaboration [1] - There is a strong focus on the development of new energy vehicles, particularly the electrification of public service vehicles such as government cars, taxis, logistics delivery vehicles, and sanitation vehicles [1] - The plan also aims to expand the demonstration application scale of hydrogen energy vehicles for construction waste transportation [1]